Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 6—June 2014

Short-Term Malaria Reduction by Single-Dose Azithromycin during Mass Drug Administration for Trachoma, Tanzania

Stephen E. Schachterle1, George Mtove, Joshua P. Levens, Emily Clemens, Lirong Shi, Amrita Raj, J. Stephen Dumler, Beatriz Munoz, Shelia West, and David J. SullivanComments to Author 
Author affiliations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (S.E. Schachterle, L. Shi, A. Raj, D.J. Sullivan); National Institute for Medical Research, Ubwari, Tanzania (G. Mtove); Johns Hopkins University School of Medicine, Baltimore (J.P. Levens, E. Clemens, J.S. Dumler, B. Munoz, S. West)

Main Article

Table 1

Comparison between azithromycin MDA treatment and control participants at baseline, Tanzania, January 12–July 21, 2009*

Variable MDA treatment group MDA control group
Bednet ownership, yes/no† 457/725 (63) 328/789 (42)
History of fever, yes/no† 26/813 (3) 10/869 (1)
Malaria medication, yes/no 157/814 (19) 161/869 (19)
Latrine access, yes/no 297/981 (30) 276/971 (28)
Education of head of household, yes/no 4.2 (3.41) 3.2 (3.46)
Altitude, m 1,206 (32.89) 1,200 (45.99)

*Values are no. positive/no. tested (%) for categorical measures or mean (SD) for continuous measures. MDA, mass drug administration.
†p<0.05 by χ2 test.

Main Article

1Current affiliation: Pfizer, Inc., New York, New York, USA.

Page created: May 16, 2014
Page updated: May 16, 2014
Page reviewed: May 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.